Early clinical trial results suggest that a groundbreaking new antibiotic drug could be a “massive game changer” for some patients suffering from chronic lower back pain.

Certain antibiotic-resistant infections could be treated with precision medicine in the future, thanks to a new resource mapping plasmids the ultimate vehicle of rapid bacterial evolution.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

For millions of years, frogs have flourished in microbial swamps yet rarely falling ill. To survive these hostile ...

Akagera Medicines, a Rwandan biotech company has announced promising results after completing early stages of preclinical trials of an antibiotic drug for the treatment of pulmonary tuberculosis (TB).

Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving breakthroughs in medicine, agriculture, and environmental sustainability. As we look ahead to ...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics continues to strip away its remaining pipeline. | ...

Engineered frog-derived peptides may become powerful new antibiotics, showing strong results against resistant bacteria in ...

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.

In seeking new antibiotic sources, researchers have turned to an unlikely source: a whiffy frog known as Odorrana andersonii.

Investment bankers say large pharma and biotech deals are stalling as executives grapple with mercurial White House economic ...